Austral Capital Partners

Andes Biotechnologies S.A. is a biotechnology company based in Santiago, Chile, focused on the research, development, and marketing of innovative anti-cancer therapies in the United States and Europe. Founded in 2010, the company specializes in nucleic acid-based drug discovery, particularly targeting solid tumor cancers. It has developed proprietary technology utilizing long non-coding RNAs, specifically sense (S-RNA) and antisense (AS-RNA), which are synthesized in mitochondria and migrate to the nucleus. These oligonucleotide drugs selectively induce apoptosis in cancer cells, leaving normal cells unharmed. Andes Biotechnologies is currently advancing its lead drug, Andes-1537, through clinical development and holds an active investigational new drug (IND) application in the United States. The company is supported by an experienced management team and a strong network of collaborators in the cancer research field, along with a comprehensive intellectual property portfolio.

Andes Biotechnologies S.A. is a biotechnology company based in Santiago, Chile, focused on the research, development, and marketing of innovative anti-cancer therapies in the United States and Europe. Founded in 2010, the company specializes in nucleic acid-based drug discovery, particularly targeting solid tumor cancers. It has developed proprietary technology utilizing long non-coding RNAs, specifically sense (S-RNA) and antisense (AS-RNA), which are synthesized in mitochondria and migrate to the nucleus. These oligonucleotide drugs selectively induce apoptosis in cancer cells, leaving normal cells unharmed. Andes Biotechnologies is currently advancing its lead drug, Andes-1537, through clinical development and holds an active investigational new drug (IND) application in the United States. The company is supported by an experienced management team and a strong network of collaborators in the cancer research field, along with a comprehensive intellectual property portfolio.

Andes Biotechnologies S.A. is a biotechnology company based in Santiago, Chile, focused on the research, development, and marketing of innovative anti-cancer therapies in the United States and Europe. Founded in 2010, the company specializes in nucleic acid-based drug discovery, particularly targeting solid tumor cancers. It has developed proprietary technology utilizing long non-coding RNAs, specifically sense (S-RNA) and antisense (AS-RNA), which are synthesized in mitochondria and migrate to the nucleus. These oligonucleotide drugs selectively induce apoptosis in cancer cells, leaving normal cells unharmed. Andes Biotechnologies is currently advancing its lead drug, Andes-1537, through clinical development and holds an active investigational new drug (IND) application in the United States. The company is supported by an experienced management team and a strong network of collaborators in the cancer research field, along with a comprehensive intellectual property portfolio.

Atakama Labs is a developer, publisher, and operator of social games, with a focus on creating meaningful gaming experiences that entertain and positively impact players' lives. The company primarily develops its games in Chile and distributes them globally, utilizing both direct publishing and partnerships based on platform and territory. Atakama Labs emphasizes accessibility by offering their games for free, allowing a broad audience to engage with their content. The company is supported by venture capital funds, including Austral Capital and the COPEC-UC Fund.